Halozyme Therapeutics, Inc. (HALO)

62.23 +0.33 (+0.53%) USD  |  NASDAQ  |  Dec 12, 10:33
More

Halozyme Therapeutics Total Expenses (% of Annual Revenues)

Total Expenses (% of Annual Revenues) Chart

View Total Expenses (% of Annual Revenues) for HALO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Total Expenses (% of Annual Revenues) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

Total Expenses (% of Annual Revenues) Range, Past 5 Years

View Total Expenses (% of Annual Revenues) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Expenses (% of Annual Revenues) Benchmarks

View Total Expenses (% of Annual Revenues) Benchmarks
Start Trial
Merck & Co., Inc. Upgrade
ANI Pharmaceuticals, Inc. Upgrade
Bristol Myers Squibb Co. Upgrade
Twist Bioscience Corp. Upgrade
Aurinia Pharmaceuticals, Inc. Upgrade